<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034121</url>
  </required_header>
  <id_info>
    <org_study_id>ELX-CL-1003 Cx</org_study_id>
    <nct_id>NCT04034121</nct_id>
  </id_info>
  <brief_title>Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry</brief_title>
  <official_title>Non-randomized Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System in de Novo Native Coronary Artery Lesions - DESolve Cx Single-Arm Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elixir Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elixir Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This additional arm of the DESolve Nx study is an evaluation of the CE Mark approved DESolve&#xD;
      Cx Novolimus Eluting Bioresorbable Scaffold System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DESolve Cx Single-Arm Registry enrolled patients using the same inclusion and exclusion&#xD;
      criteria and clinical endpoints as the DESolve Nx Study&#xD;
&#xD;
      This study was split into 2 cohorts - European and Brazilian. The European cohort (30&#xD;
      subjects) completed all follow-up at 1 year and the Brazilian cohort at 3 years (20 subjects)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2016</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically-indicated Major Adverse Cardiac Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the European and Brazilian Cohorts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-scaffold Late Lumen Loss by Quantitative Coronary Angiography (QCA)</measure>
    <time_frame>6 months</time_frame>
    <description>quantitative QCA measurement of change in the lumen diameter from post procedure and 6 months which is described as &quot;late lumen loss&quot; This applies to both the European and Brazilian Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-indicated Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to both the European and Brazilian Cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-Indicated Major Adverse Cardiac Events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This time point applies to the Brazilian Cohort only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-indicated Major Adverse Cardiac Events</measure>
    <time_frame>36 months</time_frame>
    <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the Brazilian Cohort only</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>DESolve Cx</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DESolve Cx drug eluting coronary scaffold system</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>DESolve Cx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be at least 18 years of age and for the 35-patient subset, patients must&#xD;
             be over the age of 50&#xD;
&#xD;
          -  Patient is able to verbally confirm understanding of risks, benefits and treatment&#xD;
             alternatives of receiving the DESolve Novolimus Eluting Bioresorbable Coronary&#xD;
             Scaffold System (BCSS) and he/she provides written informed consent, as approved by&#xD;
             the appropriate Ethics Committee of the respective clinical site, prior to any&#xD;
             clinical study related procedure&#xD;
&#xD;
          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,&#xD;
             silent ischemia, positive functional study or electrocardiogram (ECG) changes&#xD;
             consistent with ischemia)&#xD;
&#xD;
          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)&#xD;
             surgery&#xD;
&#xD;
          -  Patient must agree to undergo all clinical study required follow-up visits,&#xD;
             angiograms, and as applicable, imaging testing&#xD;
&#xD;
          -  Patient must agree not to participate in any other clinical study for a period of two&#xD;
             years following the index procedure&#xD;
&#xD;
          -  Target lesion must be located in a native coronary artery with a nominal vessel&#xD;
&#xD;
          -  Not part of a clinical investigation&#xD;
&#xD;
          -  Treatment of a single, non-target lesion located in a separate major epicardial vessel&#xD;
             Target vessel diameter must be a diameter of between 2.25 and 3.5 mm assessed by&#xD;
             online QCA&#xD;
&#xD;
          -  Target lesion must measure ≤ 24 mm in length&#xD;
&#xD;
          -  Target lesion must be in a major artery or branch with a visually estimated stenosis&#xD;
             of ≥ 50% and &lt; 90% with a TIMI flow of ≥ 1&#xD;
&#xD;
          -  Target vessel must be in a major coronary artery or major branch&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours&#xD;
             preceding the index procedure and cardiac enzymes have not returned within normal&#xD;
             limits at the time of procedure&#xD;
&#xD;
          -  Patient is currently experiencing clinical symptoms consistent with AMI&#xD;
&#xD;
          -  Patient requires the use of any rotablator intervention during the index procedure&#xD;
&#xD;
          -  Patient has current unstable arrhythmias&#xD;
&#xD;
          -  Patient has a known left ventricular ejection fraction (LVEF) &lt; 30%&#xD;
&#xD;
          -  Patient has received a heart transplant or any other organ transplant or is on a&#xD;
             waiting list for any organ transplant&#xD;
&#xD;
          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30&#xD;
             days prior to or after the procedure&#xD;
&#xD;
          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or&#xD;
             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus&#xD;
             etc.)&#xD;
&#xD;
          -  Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that&#xD;
             cannot be stopped and restarted according to local hospital standard procedures.&#xD;
&#xD;
          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and&#xD;
             bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast&#xD;
             sensitivity that cannot be adequately pre-medicated&#xD;
&#xD;
          -  Elective surgery is planned within the first 6 months after the procedure that will&#xD;
             require discontinuing either aspirin or clopidogrel&#xD;
&#xD;
          -  Patient has a platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3, a WBC of &lt;&#xD;
             3,000 cells/mm3, or documented or suspected liver disease.&#xD;
&#xD;
          -  Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5&#xD;
             mg/dL, or patient on dialysis)&#xD;
&#xD;
          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood&#xD;
             transfusions&#xD;
&#xD;
          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological&#xD;
             attack (TIA) within the past six months&#xD;
&#xD;
          -  Patient has had a significant GI or urinary bleed within the past six months&#xD;
&#xD;
          -  Patient has extensive peripheral vascular disease that precludes safe 6 French sheath&#xD;
             insertion&#xD;
&#xD;
          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known&#xD;
             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause&#xD;
             non-compliance with the clinical study plan, confound the data interpretation or is&#xD;
             associated with a limited life expectancy (i.e., less than one year)&#xD;
&#xD;
          -  Patient is already participating in another clinical study&#xD;
&#xD;
          -  Women of childbearing potential who have not undergone surgical sterilization or are&#xD;
             not post-menopausal (defined as amenorrheic for at least one year) as well as women&#xD;
             who are pregnant or nursing&#xD;
&#xD;
          -  Patient is unable to give their consent, is legally incompetent, or is&#xD;
             institutionalized by virtue of an order issued by the courts or other authority&#xD;
&#xD;
          -  Target lesion(s) meets any of the following criteria:&#xD;
&#xD;
          -  Aorto-ostial location&#xD;
&#xD;
          -  Left main location&#xD;
&#xD;
          -  Located within 5 mm of the origin of the LAD or LCX&#xD;
&#xD;
          -  Located within an arterial or saphenous vein graft or distal to a diseased arterial or&#xD;
             saphenous vein graft&#xD;
&#xD;
          -  Lesion involving a side branch &gt;2mm in diameter or bifurcation&#xD;
&#xD;
          -  Previous placement of a scaffold proximal to or within 10 mm of the target lesion&#xD;
&#xD;
          -  Total occlusion (TIMI flow 0), or TIMI flow &lt; 1&#xD;
&#xD;
          -  Excessive tortuosity proximal to or within the lesion&#xD;
&#xD;
          -  Angulation (≥ 45o) proximal to or within the lesion&#xD;
&#xD;
          -  Calcification moderate or heavy&#xD;
&#xD;
          -  Previous intervention restenosis&#xD;
&#xD;
          -  The target vessel contains visible thrombus&#xD;
&#xD;
          -  Another clinically significant lesion (&gt;40%) is located in the same major epicardial&#xD;
             vessel as the target lesion&#xD;
&#xD;
          -  Patient has a high probability that a procedure other than pre-dilatation and&#xD;
             scaffolding and (if necessary) post-dilatation will be required at the time of index&#xD;
             procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon or&#xD;
             brachytherapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Verheye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Antwerp Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Middelheim Hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. - Jan Ziekenhuis Z.O.L.</name>
      <address>
        <city>Genk</city>
        <zip>B-3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese</name>
      <address>
        <city>Sao Paulo</city>
        <zip>0401210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biorersorbable scaffold</keyword>
  <keyword>drug eluting</keyword>
  <keyword>novolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: European Cohort</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04034121/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Brazil Cohort</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04034121/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: European Cohort</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04034121/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 20 January 2016 and 18 July 2016 Nov 2017, 50 patients were enrolled in the study at 3 centers in Brazil (20 patients) and Belgium (30 patients)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DESolve Cx</title>
          <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
The DESolve Cx Novolimus Eluting BCSS is comprised of four main components: the Poly-L-Lactic Acid-based polymer (PLLA) stent coated with a PLLA-based polymer-drug matrix containing the anti-proliferative drug Novolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>European Cohort</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30">The European Cohort enrolled 30 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Brazil Cohort</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">The Brazil Cohort enrolled 20 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DESolve Cx</title>
          <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
The DESolve Cx Novolimus Eluting BCSS is comprised of four main components: the Poly-L-Lactic Acid-based polymer (PLLA) stent coated with a PLLA-based polymer-drug matrix containing the anti-proliferative drug Novolimus.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Risk Factors</title>
          <description>The same participant may be included in more than one category therefore the number of participants does not equal the total number of participants in the group.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family history of coronary artery disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking (previous or current)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior myocardial infarction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior percutaneous coronary intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Lesion Characteristics</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Reference Vessel Diameter</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.03" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Lumen Diameter</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.17" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lesion Length</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.16" spread="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Diameter Stenosis</title>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.20" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinically-indicated Major Adverse Cardiac Events</title>
        <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the European and Brazilian Cohorts</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DESolve Cx</title>
            <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
DESolve Cx drug eluting coronary scaffold system: percutaneous coronary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically-indicated Major Adverse Cardiac Events</title>
          <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the European and Brazilian Cohorts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-scaffold Late Lumen Loss by Quantitative Coronary Angiography (QCA)</title>
        <description>quantitative QCA measurement of change in the lumen diameter from post procedure and 6 months which is described as &quot;late lumen loss&quot; This applies to both the European and Brazilian Cohorts</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DESolve Cx</title>
            <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
DESolve Cx drug eluting coronary scaffold system: percutaneous coronary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>In-scaffold Late Lumen Loss by Quantitative Coronary Angiography (QCA)</title>
          <description>quantitative QCA measurement of change in the lumen diameter from post procedure and 6 months which is described as &quot;late lumen loss&quot; This applies to both the European and Brazilian Cohorts</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically-indicated Major Adverse Cardiac Events (MACE)</title>
        <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to both the European and Brazilian Cohorts</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DESolve Cx</title>
            <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
DESolve Cx drug eluting coronary scaffold system: percutaneous coronary intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically-indicated Major Adverse Cardiac Events (MACE)</title>
          <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to both the European and Brazilian Cohorts</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically-Indicated Major Adverse Cardiac Events</title>
        <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This time point applies to the Brazilian Cohort only</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DESolve Cx</title>
            <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
The DESolve Cx Novolimus Eluting BCSS is comprised of four main components: the Poly-L-Lactic Acid-based polymer (PLLA) stent coated with a PLLA-based polymer-drug matrix containing the anti-proliferative drug Novolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically-Indicated Major Adverse Cardiac Events</title>
          <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This time point applies to the Brazilian Cohort only</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically-indicated Major Adverse Cardiac Events</title>
        <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the Brazilian Cohort only</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DESolve Cx</title>
            <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
The DESolve Cx Novolimus Eluting BCSS is comprised of four main components: the Poly-L-Lactic Acid-based polymer (PLLA) stent coated with a PLLA-based polymer-drug matrix containing the anti-proliferative drug Novolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically-indicated Major Adverse Cardiac Events</title>
          <description>Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the Brazilian Cohort only</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Major Adverse Event data was collected at 1 month, 6 months, 1, 2 and 3 years. MACE was defined as a composite endpoint of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DESolve Cx</title>
          <description>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System&#xD;
DESolve Cx drug eluting coronary scaffold system: percutaneous coronary intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>non-clinically indicated target lesion revascularization</sub_title>
                <description>Revascularization of the target lesion not meeting the definition of clinically-indicated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Candace Elek, Executive Vice President, Clinical Research</name_or_title>
      <organization>Elixir Medical</organization>
      <phone>408-636-2020</phone>
      <email>celek@elixirmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

